{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:43Z","timestamp":1786982143499,"version":"build-2736575974"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008386","name":"Marmara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Beh\u00e7et\u2019s disease (BD) is a multisystemic inflammatory disorder in which treatment decisions are largely driven by the pattern and severity of organ involvement. This review provides a practical, organ-based overview of current therapeutic strategies for severe and refractory BD, with an emphasis on treatment selection and timing in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent evidence supports an upfront, intensive treatment approach for life-threatening or damage-prone organ involvement, particularly neurological, vascular, and ocular disease, where delays in inflammation control are closely associated with irreversible damage. Anti\u2013tumour necrosis factor agents form the core of therapy in these settings, supported by the strongest disease-specific data, while other biologic and targeted therapies are increasingly used in refractory cases. In contrast, mucocutaneous and articular manifestations predominantly affect quality of life and are commonly managed with stepwise strategies. Colchicine remains a widely used first-line treatment in routine practice and provides effective control of mucocutaneous and joint manifestations in a substantial proportion of patients, with escalation to additional systemic or targeted therapies guided by persistence, refractoriness, and patient burden. Importantly, treatment responses vary across organ systems, and benefit in one domain cannot be assumed to translate to others, reinforcing the need for organ-specific treatment planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Optimal management of BD depends on matching treatment intensity to organ-specific risk, prioritising early aggressive therapy for major organ involvement while adopting proportionate, stepwise approaches for non\u2013life-threatening disease. Improved outcomes are likely to be achieved through timely recognition of patients at risk of progression and early use of appropriately targeted therapies to prevent irreversible organ damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-026-01217-z","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:34:32Z","timestamp":1774949672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Severe Beh\u00e7et\u2019s Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Kerem","family":"Abacar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Alibaz-Oner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1217_CR1","doi-asserted-by":"crossref","unstructured":"Emmi G, Bettiol A, Hatemi G, Prisco D. Beh\u00e7et's syndrome. Lancet. 2024;403(10431):1093\u20131108.","DOI":"10.1016\/S0140-6736(23)02629-6"},{"issue":"3","key":"1217_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u2019s D","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Behcet\u2019s D. The International Criteria for Behcet\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1217_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kotter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1217_CR4","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kotter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G. Management of major organ involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018;57(12):2200\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1217_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1601-0825.2005.01173.x","volume":"12","author":"G Mumcu","year":"2006","unstructured":"Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, Yavuz S, Sur H, Atalay T, Direskeneli H. Oral health related quality of life is affected by disease activity in Behcet\u2019s disease. Oral Dis. 2006;12(2):145\u201351.","journal-title":"Oral Dis"},{"issue":"12","key":"1217_CR6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10067-014-2585-3","volume":"33","author":"F Alibaz-Oner","year":"2014","unstructured":"Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H. Unmet need in Behcet\u2019s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773\u20136.","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"1217_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","volume":"16","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut I, Barete S, Bodaghi B, Deiva K, Desbois AC, Galeotti C, Gaudric J, Kaplanski G, Mahr A, Noel N, Piram M, Tran TA, Wechsler B, Saadoun D. Collaborators. French recommendations for the management of Behcet\u2019s disease. Orphanet J Rare Dis. 2021;16(Suppl 1):352.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1217_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","volume":"43","author":"G Lawton","year":"2004","unstructured":"Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet\u2019s disease activity index. Rheumatology (Oxford). 2004;43(1):73\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1217_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behcet\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/s10165-009-0191-z","volume":"19","author":"F Shahram","year":"2009","unstructured":"Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behcet\u2019s disease. Mod Rheumatol. 2009;19(5):536\u201341.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"1217_CR11","first-page":"1033","volume":"28","author":"I Krause","year":"2001","unstructured":"Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, Weinberger A. Behcet\u2019s disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol. 2001;28(5):1033\u20136.","journal-title":"J Rheumatol"},{"key":"1217_CR12","doi-asserted-by":"crossref","unstructured":"Piga M, Floris A, Espinosa G, Serpa Pinto L, Kougkas N, Lo Monaco A, Lopalco G, Orlando I, Pirani V, Santos E, Bertsias G, Cantarini L, Cauli A, Cervera R, Correia J, Govoni M, Iannone F, Neri P, Martins Silva A, Vasconcelos C, Muntoni M, Mathieu A. the BPG. Development and preliminary validation of the Behcet\u2019s syndrome Overall Damage Index (BODI). RMD Open. 2020;6(2).","DOI":"10.1136\/rmdopen-2020-001192"},{"issue":"12","key":"1217_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","volume":"11","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. MHC-I-opathy\u2019-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 2015;11(12):731\u201340.","journal-title":"Nat Rev Rheumatol"},{"issue":"24","key":"1217_CR14","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1073\/pnas.1406575111","volume":"111","author":"MJ Ombrello","year":"2014","unstructured":"Ombrello MJ, Kirino Y, de Bakker PI, Gul A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2014;111(24):8867\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1217_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1136\/ard-2022-222852","volume":"82","author":"JJ Kuiper","year":"2023","unstructured":"Kuiper JJ, Prinz JC, Stratikos E, Kusnierczyk P, Arakawa A, Springer S, Mintoff D, Padjen I, Shumnalieva R, Vural S, Kotter I, van de Sande MG, Boyvat A, de Boer JH, Bertsias G, de Vries N, Krieckaert CL, Leal I, Vidovic Valentincic N, Tugal-Tutkun I, El Khaldi Ahanach H, Costantino F, Glatigny S, Mrazovac Zimak D, Lotscher F, Kerstens FG, Bakula M, Viera Sousa E, Bohm P, Bosman K, Kenna TJ, Powis SJ, Breban M, Gul A, Bowes J, Lories RJ, Nowatzky J, Wolbink GJ, McGonagle DG, Turkstra F. MHC-I-opathies Es. EULAR study group on \u2018MHC-I-opathy\u2019: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023;82(7):887\u201396.","journal-title":"Ann Rheum Dis"},{"key":"1217_CR16","doi-asserted-by":"publisher","first-page":"1439371","DOI":"10.3389\/fimmu.2024.1439371","volume":"15","author":"K Abacar","year":"2024","unstructured":"Abacar K, Macleod T, Direskeneli H, McGonagle D. How underappreciated autoinflammatory (innate immunity) mechanisms dominate disparate autoimmune disorders. Front Immunol. 2024;15:1439371.","journal-title":"Front Immunol"},{"key":"1217_CR17","doi-asserted-by":"crossref","unstructured":"Abacar K, Macleod T, Direskeneli H, McGonagle D. Takayasu arteritis: a geographically distant but immunologically proximal MHC-I-opathy. Lancet Rheumatol. 2025;7(4):e290\u2013302.","DOI":"10.1016\/S2665-9913(24)00307-2"},{"issue":"Suppl 1","key":"1217_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/1756-185X.13298","volume":"22","author":"F Alibaz-Oner","year":"2019","unstructured":"Alibaz-Oner F, Direskeneli H. Management of vascular Behcet\u2019s disease. Int J Rheum Dis. 2019;22(Suppl 1):105\u20138.","journal-title":"Int J Rheum Dis"},{"issue":"20","key":"1217_CR19","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoglu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Trial of Apremilast for Oral Ulcers in Behcet\u2019s Syndrome. N Engl J Med. 2019;381(20):1918\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"1217_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443\u201350.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1217_CR21","first-page":"194","volume":"1","author":"IM Ghobrial","year":"2003","unstructured":"Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1(3):194\u2013205.","journal-title":"J Support Oncol"},{"key":"1217_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Behcet\u2019s syndrome: A preliminary study. J Autoimmun. 2019;97:108\u201313.","journal-title":"J Autoimmun"},{"issue":"8","key":"1217_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni F, Bettiol A, Talarico R, Lopalco G, Silvestri E, Urban ML, Russo PAJ, Di Scala G, Emmi G, Prisco D. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet\u2019s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098\u2013104.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 108","key":"1217_CR24","first-page":"130","volume":"35","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet\u2019s disease. Clin Exp Rheumatol. 2017;35(Suppl 108):130\u20131.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1217_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/art.40912","volume":"71","author":"A Mirouse","year":"2019","unstructured":"Mirouse A, Barete S, Desbois AC, Comarmond C, Sene D, Domont F, Bodaghi B, Ferfar Y, Cacoub P, Saadoun D. French Behcet\u2019s N. Long-Term Outcome of Ustekinumab Therapy for Behcet\u2019s Disease. Arthritis Rheumatol. 2019;71(10):1727\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1217_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.46497\/ArchRheumatol.2024.11049","volume":"39","author":"B Sulu","year":"2024","unstructured":"Sulu B, Hatemi G. New and future perspectives in Behcet\u2019s syndrome. Arch Rheumatol. 2024;39(4):511\u201321.","journal-title":"Arch Rheumatol"},{"issue":"12","key":"1217_CR27","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1136\/ard-2024-225913","volume":"83","author":"EE Ghayad","year":"2024","unstructured":"Ghayad EE, Maalouf G, Mekinian A, Emmi G, Vieira M, Mirouse A, Desbois AC, Le Joncour A, Domont F, Leroux G, Bugaut H, Vautier M, Cacoub P, Barete S, Saadoun D. Guselkumab in Behcet\u2019s disease. Ann Rheum Dis. 2024;83(12):1794\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1217_CR28","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/1346-8138.15553","volume":"47","author":"G Mumcu","year":"2020","unstructured":"Mumcu G, Yay M, Karacayli U, Aksoy A, Tas MN, Armagan B, Sari A, Bozca BC, Tekgoz E, Temiz Karadag D, Badak SO, Tecer D, Yildirim A, Bes C, Sahin A, Erken E, Cefle A, Cinar M, Yilmaz S, Alpsoy E, Boyvat A, Senel S, Bilge SY, Kasifoglu T, Karadag O, Aksu K, Keser G, Alibaz-Oner F, Inanc N, Ergun T, Direskeneli H. Moderation analysis exploring associations between age and mucocutaneous activity in Behcet\u2019s syndrome: A multicenter study from Turkey. J Dermatol. 2020;47(12):1403\u201310.","journal-title":"J Dermatol"},{"issue":"4","key":"1217_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5152\/eurjrheum.2018.18094","volume":"5","author":"M Iris","year":"2018","unstructured":"Iris M, Ozcikmak E, Aksoy A, Alibaz-Oner F, Inanc N, Ergun T, Direskeneli H, Mumcu G. The assessment of contributing factors to oral ulcer presence in Behcet\u2019s disease: Dietary and non-dietary factors. Eur J Rheumatol. 2018;5(4):240\u20133.","journal-title":"Eur J Rheumatol"},{"issue":"3","key":"1217_CR30","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.4317\/medoral.26319","volume":"29","author":"EN Altingoz","year":"2024","unstructured":"Altingoz EN, Yenisoy Y, Kapusuz A, Abacar K, Sisman-Kitapci N, Yay M, Karacayli U, Alibaz-Oner F, Inanc N, Ergun T, Fortune F, Direskeneli H, Mumcu G. The mediator role of treatment response on oral health related quality of life in Behcet\u2019s syndrome. Med Oral Patol Oral Cir Bucal. 2024;29(3):e350\u20135.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"1217_CR31","first-page":"653806","volume":"2012","author":"A Bicer","year":"2012","unstructured":"Bicer A. Musculoskeletal Findings in Behcet\u2019s Disease. Patholog Res Int. 2012;2012:653806.","journal-title":"Patholog Res Int"},{"issue":"5","key":"1217_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/ard.42.5.505","volume":"42","author":"S Yurdakul","year":"1983","unstructured":"Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, Ozyazgan Y, Tuzuner N, Muftuoglu A. The arthritis of Behcet\u2019s disease: a prospective study. Ann Rheum Dis. 1983;42(5):505\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1217_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm10215174","volume":"10","author":"H Zajac","year":"2021","unstructured":"Zajac H, Turno-Krecicka A. Ocular Manifestations of Behcet\u2019s Disease: An Update on Diagnostic Challenges and Disease Management. J Clin Med. 2021;10:21.","journal-title":"J Clin Med"},{"key":"1217_CR34","doi-asserted-by":"crossref","unstructured":"Joubert M, Desbois AC, Domont F, Ghembaza A, Le Joncour A, Mirouse A, Maalouf G, Leclercq M, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Beh\u00e7et's Disease Uveitis. J Clin Med. 2023;12(11):3648.","DOI":"10.3390\/jcm12113648"},{"issue":"Suppl 127","key":"1217_CR35","first-page":"86","volume":"38","author":"C Posarelli","year":"2020","unstructured":"Posarelli C, Maglionico MN, Talarico R, Covello G, Figus M. Behcet\u2019s syndrome and ocular involvement: changes over time. Clin Exp Rheumatol. 2020;38(Suppl 127):86\u201393.","journal-title":"Clin Exp Rheumatol"},{"key":"1217_CR36","doi-asserted-by":"crossref","unstructured":"Gueudry J, Leclercq M, Saadoun D, Bodaghi B. Old and New Challenges in Uveitis Associated with Behcet\u2019s Disease. J Clin Med. 2021;10(11):2318.","DOI":"10.3390\/jcm10112318"},{"issue":"4","key":"1217_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N. Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423\u201331.","journal-title":"Br J Ophthalmol"},{"issue":"4 Suppl 34","key":"1217_CR38","first-page":"S14","volume":"22","author":"B Wechsler","year":"2004","unstructured":"Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, Fain O, LeHoang P, Piette JC. Infliximab in refractory uveitis due to Behcet\u2019s disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1217_CR39","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gul A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478\u201384.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1217_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1217_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active behcet\u2019s uveitis: an open-label trial. Rheumatol Int. 2008;29(1):53\u20137.","journal-title":"Rheumatol Int"},{"key":"1217_CR42","doi-asserted-by":"publisher","first-page":"1095423","DOI":"10.3389\/fmed.2023.1095423","volume":"10","author":"M Takeuchi","year":"2023","unstructured":"Takeuchi M, Usui Y, Namba K, Keino H, Takeuchi M, Takase H, Kamoi K, Hase K, Ito T, Nakai K, Maruyama K, Kobayashi E, Mashimo H, Sato T, Ohguro N, Hori J, Okada AA, Sonoda KH, Mizuki N, Goto H. Ten-year follow-up of infliximab treatment for uveitis in Behcet disease patients: A multicenter retrospective study. Front Med (Lausanne). 2023;10:1095423.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1217_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behcet\u2019s Disease Research Group Of J. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1217_CR44","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s10384-025-01206-2","volume":"69","author":"C Lee","year":"2025","unstructured":"Lee C, Takeuchi M, Kawagoe T, Nakamura J, Shibuya E, Ishihara M, Yamada N, Mizuki Y, Meguro A, Kirino Y, Soejima Y, Hirahara L, Iizuka Y, Mizuki N. Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behcet\u2019s disease. Jpn J Ophthalmol. 2025;69(5):798\u2013804.","journal-title":"Jpn J Ophthalmol"},{"issue":"4 Suppl 84","key":"1217_CR45","first-page":"S58","volume":"32","author":"E Interlandi","year":"2014","unstructured":"Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behcet\u2019s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58\u201362.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1217_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L. Efficacy and safety of adalimumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183\u20139.","journal-title":"Clin Rheumatol"},{"key":"1217_CR47","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","volume":"93","author":"S Yang","year":"2021","unstructured":"Yang S, Huang Z, Liu X, Li H, Xie L, Chen X, Wen F, Liang D, Su W. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behcet\u2019s uveitis with vasculitis. Int Immunopharmacol. 2021;93:107430.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1217_CR48","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40123-021-00387-6","volume":"10","author":"J Sota","year":"2021","unstructured":"Sota J, Gentileschi S, Perfetti MO, Frediani B, Tosi GM, Cantarini L, Fabiani C. Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behcet\u2019s Syndrome. Ophthalmol Ther. 2021;10(4):1129\u201335.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1217_CR49","doi-asserted-by":"publisher","first-page":"e15096","DOI":"10.1111\/1756-185X.15096","volume":"27","author":"X Guan","year":"2024","unstructured":"Guan X, Zhao Z, Xin M, Xia G, Yang Q, Fu M. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet\u2019s uveitis: A systematic review and meta-analysis. Int J Rheum Dis. 2024;27(2):e15096.","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"1217_CR50","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375(10):932\u201343.","journal-title":"N Engl J Med"},{"issue":"10050","key":"1217_CR51","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brezin AP. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183\u201392.","journal-title":"Lancet"},{"issue":"5","key":"1217_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I Kotter","year":"2004","unstructured":"Kotter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Peter HH, Stubiger N. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):311\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1217_CR53","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Koksal S, Karagul S, Bayraktar MZ. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet\u2019s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430\u20135.","journal-title":"Ophthalmology"},{"issue":"1","key":"1217_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1217_CR55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34(7):1293\u2013301.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1217_CR56","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1217_CR57","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gul A. Use of Gevokizumab in Patients with Behcet\u2019s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocul Immunol Inflamm. 2018;26(7):1023\u201333.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"1217_CR58","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","volume":"57","author":"B Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, Atanes A, Cordero-Coma M, Miquel Nolla J, Carrasco-Cubero C, Loricera J, Gonzalez-Vela MC, Vegas-Revenga N, Fernandez-Diaz C, Demetrio-Pablo R, Dominguez-Casas LC, Martin-Varillas L, Palmou-Fontana J, Hernandez N, Gonzalez-Gay JL, Blanco MA. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet\u2019s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856\u201364.","journal-title":"Rheumatology (Oxford)"},{"key":"1217_CR59","doi-asserted-by":"publisher","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","volume":"58","author":"N Barroso-Garcia","year":"2023","unstructured":"Barroso-Garcia N, Atienza-Mateo B, Ferraz-Amaro I, Prieto-Pena D, Beltran E, Adan A, Hernandez-Garfella M, Martinez-Costa L, Cordero-Coma M, Diaz-Llopis M, Herreras JM, Maiz-Alonso O, Torre-Salaberri I, De Vicente-Delmas A, Diaz-Valle D, Atanes-Sandoval A, Francisco F, Insua S, Sanchez J, Almodovar-Gonzalez R, Jimenez-Sosa A, Ruiz-Moreno O, Gandia-Martinez M, Nolla JM, Calvo-Rio V, Castaneda S, Gonzalez-Gay MA, Blanco R. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1217_CR60","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","volume":"129","author":"M Leclercq","year":"2022","unstructured":"Leclercq M, Andrillon A, Maalouf G, Seve P, Bielefeld P, Gueudry J, Sene T, Moulinet T, Rouviere B, Sene D, Desbois AC, Domont F, Touhami S, El Chamieh C, Cacoub P, Bodaghi B, Biard L, Saadoun D. Anti-Tumor Necrosis Factor alpha versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Ophthalmology. 2022;129(5):520\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"1217_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, Franceschini R, Bacherini D, Frediani B, Galeazzi M, Tosi GM, Cantarini L. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behcet\u2019s Disease. Ocul Immunol Inflamm. 2019;27(1):58\u201363.","journal-title":"Ocul Immunol Inflamm"},{"key":"1217_CR62","doi-asserted-by":"crossref","unstructured":"Cordero-Coma M, Calvo-Rio V, Adan A, Blanco R, Alvarez-Castro C, Mesquida M, Calleja S, Gonzalez-Gay MA, Ruiz, de Morales JG. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;2014:717598.","DOI":"10.1155\/2014\/717598"},{"issue":"4","key":"1217_CR63","first-page":"680","volume":"37","author":"GM Tosi","year":"2019","unstructured":"Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, Guerriero S, Orlando I, Iannone F, Frediani B, Angotti R, Messina M, Galeazzi M, Vannozzi L, Cantarini L, Fabiani C. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37(4):680\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"1217_CR64","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Varillas JL, Sanchez-Bilbao L, Calvo-R\u00edo V, Ad\u00e1n A, Hernanz I, Gallego-Flores A, Beltran-Catalan E, Castro-Oreiro S, Fanlo P, Garcia Martos A, Torre I, Cordero-Coma M, De Dios JR, Garc\u00eda-Aparicio \u00c1, Hern\u00e1ndez-Garfella M, S\u00e1nchez-Andrade A, Garc\u00eda-Valle A, Maiz O, Migu\u00e9lez R, Rodr\u00edguez-Montero S, Urruticoechea A, Veroz R, Conesa A, Fern\u00e1ndez-Carballido C, Jovan\u00ed V, Mondejar JJ, Mart\u00ednez Gonz\u00e1lez O, Moya Alvarado P, Romero-Yuste S, Rubio-Mu\u00f1oz P, Pe\u00f1a-Sainz-Pardo E, Garijo-Bufort M, Demetrio-Pablo R, Hern\u00e1ndez JL, Blanco R. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022;8(2):e002693.","DOI":"10.1136\/rmdopen-2022-002693"},{"issue":"Pt 11","key":"1217_CR65","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet\u2019s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain. 1999;122(Pt 11):2171\u201382.","journal-title":"Brain"},{"issue":"3","key":"1217_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00019052-200406000-00017","volume":"17","author":"A Siva","year":"2004","unstructured":"Siva A, Altintas A, Saip S. Behcet\u2019s syndrome and the nervous system. Curr Opin Neurol. 2004;17(3):347\u201357.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"1217_CR67","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.38351","volume":"66","author":"N Noel","year":"2014","unstructured":"Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, Piette JC, Drier A, Dormont D, Cacoub P, Saadoun D. Long-term outcome of neuro-Behcet\u2019s disease. Arthritis Rheumatol. 2014;66(5):1306\u201314.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1217_CR68","doi-asserted-by":"publisher","first-page":"EVIDoa2300354","DOI":"10.1056\/EVIDoa2300354","volume":"3","author":"D Saadoun","year":"2024","unstructured":"Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, Plessier A, Sene T, Kone-Paut I, Noel N, Mekinian A, Lambert M, Ribeiro E, Mirault T, Mele N, Dellal A, Fain O, Melki I, Chiche L, Gaudric J, Redheuil A, Maillart E, Ghembaza A, Desbois AC, Mirouse A, Domont F, Leroux G, Ferfar Y, Rigolet A, Viallard JF, Vautier M, Resche-Rigon M, Cacoub P. Infliximab versus Cyclophosphamide for Severe Behcet\u2019s Syndrome. NEJM Evid. 2024;3(11):EVIDoa2300354.","journal-title":"NEJM Evid"},{"issue":"6","key":"1217_CR69","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.4240\/wjgs.v16.i6.1493","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Gao F, Yang DQ, Jiao Y. Intestinal Behcet\u2019s disease: A review of clinical diagnosis and treatment. World J Gastrointest Surg. 2024;16(6):1493\u2013500.","journal-title":"World J Gastrointest Surg"},{"issue":"3","key":"1217_CR70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5217\/ir.2017.15.3.311","volume":"15","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behcet\u2019s disease. Intest Res. 2017;15(3):311\u20137.","journal-title":"Intest Res"},{"issue":"9","key":"1217_CR71","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00535-007-2090-4","volume":"42","author":"K Kobayashi","year":"2007","unstructured":"Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Igarashi M, Iizuka BE, Matsuda T, Matsui T, Matsumoto T, Sugita A, Takeno M, Hibi T. Development of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease using a modified Delphi approach. J Gastroenterol. 2007;42(9):737\u201345.","journal-title":"J Gastroenterol"},{"issue":"7","key":"1217_CR72","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, Arai K, Uchino M, Koganei K, Kobayashi T, Takeno M, Ueno F, Matsumoto T, Mizuki N, Suzuki Y, Hisamatsu T. Evidence-based diagnosis and clinical practice guidelines for intestinal Behcet\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55(7):679\u2013700.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1217_CR73","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5217\/ir.2017.15.3.318","volume":"15","author":"T Hisamatsu","year":"2017","unstructured":"Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behcet\u2019s disease. Intest Res. 2017;15(3):318\u201327.","journal-title":"Intest Res"},{"issue":"5","key":"1217_CR74","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3349\/ymj.2013.54.5.1084","volume":"54","author":"JJ Park","year":"2013","unstructured":"Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet\u2019s disease. Yonsei Med J. 2013;54(5):1084\u201390.","journal-title":"Yonsei Med J"},{"issue":"3","key":"1217_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clinthera.2023.12.012","volume":"46","author":"X Zu","year":"2024","unstructured":"Zu X, Xiong S, Lu Y, Zhang N, Xu S, Feng R, Chen B, Zeng Z, Chen M, He Y. Predicting Factors of Long-term Outcome of Gastrointestinal Behcet\u2019s Disease: A Chinese Retrospective Study. Clin Ther. 2024;46(3):201\u20137.","journal-title":"Clin Ther"},{"issue":"9","key":"1217_CR76","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, Kim HJ, Kim EY, Kim KO, Jang BI, Kim WH. Efficacy of infliximab in intestinal Behcet\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19(9):1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"17","key":"1217_CR77","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","volume":"52","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S. Efficacy of infliximab in patients with intestinal Behcet\u2019s disease refractory to conventional medication. Intern Med. 2013;52(17):1855\u201362.","journal-title":"Intern Med"},{"issue":"5","key":"1217_CR78","doi-asserted-by":"publisher","first-page":"777","DOI":"10.5009\/gnl220278","volume":"17","author":"JH Cheon","year":"2023","unstructured":"Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, Ye BD, Song GA, Lee Y, Kim Y, Lee Y, Kim WH, Group BS. Efficacy and Safety of Infliximab in Intestinal Behcet\u2019s Disease: A Multicenter, Phase 3 Study (BEGIN). Gut Liver. 2023;17(5):777\u201385.","journal-title":"Gut Liver"},{"issue":"3","key":"1217_CR79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T. Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15(3):395\u2013401.","journal-title":"Intest Res"},{"issue":"3","key":"1217_CR80","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5217\/ir.2020.00013","volume":"19","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet\u2019s disease: results from a large real-world observational study. Intest Res. 2021;19(3):301\u201312.","journal-title":"Intest Res"},{"issue":"6 Suppl 94","key":"1217_CR81","first-page":"S129","volume":"33","author":"I Hatemi","year":"2015","unstructured":"Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet\u2019s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129\u201337.","journal-title":"Clin Exp Rheumatol"},{"key":"1217_CR82","doi-asserted-by":"publisher","first-page":"769785","DOI":"10.3389\/fimmu.2021.769785","volume":"12","author":"M Arbrile","year":"2021","unstructured":"Arbrile M, Radin M, Rossi D, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Vedolizumab for the Management of Refractory Behcet\u2019s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. Front Immunol. 2021;12:769785.","journal-title":"Front Immunol"},{"key":"1217_CR83","doi-asserted-by":"publisher","first-page":"1759720X2211240","DOI":"10.1177\/1759720X221124014","volume":"14","author":"J Zou","year":"2022","unstructured":"Zou J, Cai JF, Ye JF, Guan JL. Tofacitinib as an alternative therapy for refractory intestinal Behcet\u2019s syndrome. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124014.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1217_CR84","doi-asserted-by":"publisher","first-page":"981502","DOI":"10.3389\/fimmu.2022.981502","volume":"13","author":"N Zhao","year":"2022","unstructured":"Zhao N, Tang Y, Wang S, Cui L, Sun X, Wang Z, Liu Y. Case report: Refractory intestinal Behcet\u2019s syndrome successfully treated with tofacitinib: A report of four cases. Front Immunol. 2022;13:981502.","journal-title":"Front Immunol"},{"key":"1217_CR85","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu J, Yu X, Wang Z, Liu W, Liu X, Wang X, Zhang M, Zhao Y, Zhang F, Yang H, Zheng W. Baricitinib for the treatment of intestinal Behcet\u2019s disease: A pilot study. Clin Immunol. 2023;247:109241.","journal-title":"Clin Immunol"},{"key":"1217_CR86","doi-asserted-by":"publisher","first-page":"1483993","DOI":"10.3389\/fimmu.2024.1483993","volume":"15","author":"S Sha","year":"2024","unstructured":"Sha S, Xu B, Wang K, Qiao C, Shi H, Jiang J, Quan X, Liu X. Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behcet\u2019s disease. Front Immunol. 2024;15:1483993.","journal-title":"Front Immunol"},{"issue":"11","key":"1217_CR87","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","volume":"79","author":"J Liu","year":"2020","unstructured":"Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, Zeng X, Zhang F, Zheng W. A pilot study of tofacitinib for refractory Behcet\u2019s syndrome. Ann Rheum Dis. 2020;79(11):1517\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1217_CR88","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","volume":"19","author":"A Bettiol","year":"2023","unstructured":"Bettiol A, Alibaz-Oner F, Direskeneli H, Hatemi G, Saadoun D, Seyahi E, Prisco D, Emmi G. Vascular Behcet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol. 2023;19(2):111\u201326.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"1217_CR89","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","volume":"117","author":"V Hamuryudan","year":"2004","unstructured":"Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, Yurdakul S, Numan F, Yazici H. Pulmonary artery aneurysms in Behcet syndrome. Am J Med. 2004;117(11):867\u201370.","journal-title":"Am J Med"},{"issue":"1","key":"1217_CR90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/rheumatology\/33.1.48","volume":"33","author":"V Hamuryudan","year":"1994","unstructured":"Hamuryudan V, Yurdakul S, Moral F, Numan F, Tuzun H, Tuzuner N, Mat C, Tuzun Y, Ozyazgan Y, Yazici H. Pulmonary arterial aneurysms in Behcet\u2019s syndrome: a report of 24 cases. Br J Rheumatol. 1994;33(1):48\u201351.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"1217_CR91","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jvsv.2016.01.003","volume":"4","author":"F Alibaz-Oner","year":"2016","unstructured":"Alibaz-Oner F, Aldag B, Aldag M, Unal AU, Mutis A, Toptas T, Ergun T, Direskeneli H. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behcet\u2019s disease. J Vasc Surg Venous Lymphat Disord. 2016;4(3):301\u20136.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"4","key":"1217_CR92","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","volume":"59","author":"Y Ozguler","year":"2020","unstructured":"Ozguler Y, Hatemi G, Cetinkaya F, Tascilar K, Hamuryudan V, Ugurlu S, Seyahi E, Yazici H, Melikoglu M. Clinical course of acute deep vein thrombosis of the legs in Behcet\u2019s syndrome. Rheumatology (Oxford). 2020;59(4):799\u2013806.","journal-title":"Rheumatology (Oxford)"},{"key":"1217_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","volume":"197","author":"AC Desbois","year":"2018","unstructured":"Desbois AC, Biard L, Addimanda O, Lambert M, Hachulla E, Launay D, Ackermann F, Perard L, Hot A, Maurier F, Mausservey C, Bernard F, Noel N, Alric L, Mirault T, Cohen F, Boussouar S, Resche-Rigon M, Cacoub P, Saadoun D. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: A multicenter observational study of 18 patients. Clin Immunol. 2018;197:54\u20139.","journal-title":"Clin Immunol"},{"issue":"8","key":"1217_CR94","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, Koskas F, Desseaux K, Cacoub P, Saadoun D. Immunosuppressants reduce venous thrombosis relapse in Behcet\u2019s disease. Arthritis Rheum. 2012;64(8):2753\u201360.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1217_CR95","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.semarthrit.2014.10.014","volume":"44","author":"E Seyahi","year":"2015","unstructured":"Seyahi E, Caglar E, Ugurlu S, Kantarci F, Hamuryudan V, Sonsuz A, Melikoglu M, Yurdakul S, Yazici H. An outcome survey of 43 patients with Budd-Chiari syndrome due to Behcet\u2019s syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 2015;44(5):602\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1217_CR96","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","volume":"46","author":"E Seyahi","year":"2007","unstructured":"Seyahi E, Hamuryudan V, Hatemi G, Melikoglu M, Celik S, Fresko I, Yurdakul S, Yazici H. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet\u2019s syndrome. Rheumatology (Oxford). 2007;46(7):1213\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1217_CR97","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RHU.0000000000002137","volume":"30","author":"KY Abacar","year":"2024","unstructured":"Abacar KY, Boncukcuoglu AE, Aksoy A, Kocakaya D, Cimsit C, Direskeneli H, Alibaz-Oner F. Anticoagulant Treatment May Decrease the Relapse Rate of Pulmonary Arterial Involvement in Behcet\u2019s Disease. J Clin Rheumatol. 2024;30(8):303\u20138.","journal-title":"J Clin Rheumatol"},{"key":"1217_CR98","doi-asserted-by":"publisher","first-page":"109682","DOI":"10.1016\/j.clim.2023.109682","volume":"253","author":"G Hatemi","year":"2023","unstructured":"Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, Melikoglu M, Ugurlu S, Fresko I, Siva A, Kutlubay Z, Yurdakul S, Yazici H, Hamuryudan V. Infliximab for vascular involvement in Behcet\u2019s syndrome. Clin Immunol. 2023;253:109682.","journal-title":"Clin Immunol"},{"issue":"2","key":"1217_CR99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/s-0037-1604411","volume":"66","author":"SO Yildizeli","year":"2018","unstructured":"Yildizeli SO, Yanartas M, Tas S, Direskeneli H, Mutlu B, Ceyhan B, Yildizeli B. Outcomes of Patients with Behcet\u2019s Syndrome after Pulmonary Endarterectomy. Thorac Cardiovasc Surg. 2018;66(2):187\u201392.","journal-title":"Thorac Cardiovasc Surg"},{"issue":"4 Suppl 60","key":"1217_CR100","first-page":"S79","volume":"28","author":"G Espinosa","year":"2010","unstructured":"Espinosa G, Blanco I, Anton JM, Sanchez M, Macchiarini P, Barbera JA. Chronic thromboembolic pulmonary hypertension in Behcet\u2019s disease: effectiveness of endarterectomy. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S79\u201381.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1217_CR101","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jvscit.2022.02.006","volume":"8","author":"N Law","year":"2022","unstructured":"Law N, Quencer K, Kaufman C, Iravani A, Hardman R, Smith T. Embolization of pulmonary artery aneurysms in a patient with Behcet\u2019s disease complicated by coil erosion into the airway. J Vasc Surg Cases Innov Tech. 2022;8(2):193\u20135.","journal-title":"J Vasc Surg Cases Innov Tech"},{"issue":"7","key":"1217_CR102","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","volume":"61","author":"H Zhong","year":"2022","unstructured":"Zhong H, Liu T, Liu Y, Zhang X, Zhou Y, Su Y. Efficacy and safety of tocilizumab in Behcet\u2019s syndrome with refractory arterial lesions: a single-centre observational cohort study in China. Rheumatology (Oxford). 2022;61(7):2923\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1217_CR103","first-page":"2057","volume":"42","author":"A Ozdede","year":"2024","unstructured":"Ozdede A, Esatoglu SN, Durmaz ES, Karakoc A, Ogun H, Hatemi G, Melikoglu M, Seyahi E. Tocilizumab may not be a good option for vascular involvement due to Behcet\u2019s syndrome. Clin Exp Rheumatol. 2024;42(10):2057\u201364.","journal-title":"Clin Exp Rheumatol"},{"key":"1217_CR104","doi-asserted-by":"publisher","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","volume":"250","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang X, Liu W, Wang Y, Liu J, Zhang L, Zhang S, Tian X, Zhao Y, Zheng W. Baricitinib for the treatment of refractory vascular Behcet\u2019s disease. Clin Immunol. 2023;250:109298.","journal-title":"Clin Immunol"},{"key":"1217_CR105","doi-asserted-by":"publisher","first-page":"109263","DOI":"10.1016\/j.clim.2023.109263","volume":"248","author":"T Bozkurt","year":"2023","unstructured":"Bozkurt T, Karabacak M, Karatas H, Kutlug Agackiran S, Ergun T, Direskeneli H, Alibaz-Oner F. Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behcet\u2019s disease. Clin Immunol. 2023;248:109263.","journal-title":"Clin Immunol"},{"issue":"16","key":"1217_CR106","doi-asserted-by":"publisher","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet\u2019s Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. Med (Baltim). 2016;95(16):e3348.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1217_CR107","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/ijd.ijd_719_24","volume":"70","author":"YK Ren","year":"2025","unstructured":"Ren YK, Ren L, Sun W, Liu HY, Guo SP. Paradoxical Behcet\u2019s Disease after Ixekizumab: A Case Report and Literature Review. Indian J Dermatol. 2025;70(1):42\u20136.","journal-title":"Indian J Dermatol"},{"issue":"5","key":"1217_CR108","doi-asserted-by":"publisher","first-page":"omz041","DOI":"10.1093\/omcr\/omz041","volume":"2019","author":"E Dincses","year":"2019","unstructured":"Dincses E, Yurttas B, Esatoglu SN, Melikoglu M, Hamuryudan V, Seyahi E. Secukinumab induced Behcet\u2019s syndrome: a report of two cases. Oxf Med Case Rep. 2019;2019(5):omz041.","journal-title":"Oxf Med Case Rep"},{"issue":"9","key":"1217_CR109","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1093\/rheumatology\/keab944","volume":"61","author":"NB Tukek","year":"2022","unstructured":"Tukek NB, Esatoglu SN, Hatemi G, Caliskan EB, Ozyazgan Y, Ucar D, Ozguler Y, Seyahi E, Melikoglu M, Uygunoglu U, Siva A, Kutlubay Z, Hatemi I, Celik AF, Ugurlu S, Fresko I, Yurdakul S, Yazici H, Hamuryudan V. Emergence of new manifestations during infliximab treatment in Behcet\u2019s syndrome. Rheumatology (Oxford). 2022;61(9):3746\u201353.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01217-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01217-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01217-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:13:59Z","timestamp":1781644439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01217-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01217-z","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"11"}}